Aspreva cuts a quarter of its jobs as it refocuses

Canada's Aspreva Pharmaceuticals says that Chief Scientific Officer Richard Jones is leaving the company as the biotech cuts 33 jobs, or about a quarter of its work force. Company officials say they want to concentrate on their core functions. Aspreva recently completed a late-stage trial for an experimental therapy for myasthenia gravis and another trial for a treatment of lupus nephritis. Aspreva says it remains committed to a pact it has with Roche.

- see the release
- here's the report from Canada East

Related Articles:
Aspreva's CellCept fails late-stage superiority study. Report
Aspreva Pharmaceuticals drug fails Phase III trial. Report
CellCept wins orphan status. Report